JP2013522367A5 - - Google Patents

Download PDF

Info

Publication number
JP2013522367A5
JP2013522367A5 JP2013501396A JP2013501396A JP2013522367A5 JP 2013522367 A5 JP2013522367 A5 JP 2013522367A5 JP 2013501396 A JP2013501396 A JP 2013501396A JP 2013501396 A JP2013501396 A JP 2013501396A JP 2013522367 A5 JP2013522367 A5 JP 2013522367A5
Authority
JP
Japan
Prior art keywords
cem
diffraction pattern
powder diffraction
ray powder
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013501396A
Other languages
English (en)
Japanese (ja)
Other versions
JP5711352B2 (ja
JP2013522367A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/029424 external-priority patent/WO2011119604A1/en
Publication of JP2013522367A publication Critical patent/JP2013522367A/ja
Publication of JP2013522367A5 publication Critical patent/JP2013522367A5/ja
Application granted granted Critical
Publication of JP5711352B2 publication Critical patent/JP5711352B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013501396A 2010-03-22 2011-03-22 マクロライドの結晶形、およびその使用 Active JP5711352B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31606310P 2010-03-22 2010-03-22
US61/316,063 2010-03-22
PCT/US2011/029424 WO2011119604A1 (en) 2010-03-22 2011-03-22 Crystalline forms of a macrolide, and uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014231987A Division JP6121387B2 (ja) 2010-03-22 2014-11-14 マクロライドの結晶形、およびその使用

Publications (3)

Publication Number Publication Date
JP2013522367A JP2013522367A (ja) 2013-06-13
JP2013522367A5 true JP2013522367A5 (enExample) 2014-05-15
JP5711352B2 JP5711352B2 (ja) 2015-04-30

Family

ID=44673574

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013501396A Active JP5711352B2 (ja) 2010-03-22 2011-03-22 マクロライドの結晶形、およびその使用
JP2014231987A Active JP6121387B2 (ja) 2010-03-22 2014-11-14 マクロライドの結晶形、およびその使用
JP2016244733A Pending JP2017081953A (ja) 2010-03-22 2016-12-16 マクロライドの結晶形、およびその使用
JP2019163614A Pending JP2020002168A (ja) 2010-03-22 2019-09-09 マクロライドの結晶形、およびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014231987A Active JP6121387B2 (ja) 2010-03-22 2014-11-14 マクロライドの結晶形、およびその使用
JP2016244733A Pending JP2017081953A (ja) 2010-03-22 2016-12-16 マクロライドの結晶形、およびその使用
JP2019163614A Pending JP2020002168A (ja) 2010-03-22 2019-09-09 マクロライドの結晶形、およびその使用

Country Status (19)

Country Link
US (4) US8975386B2 (enExample)
EP (2) EP3009442B1 (enExample)
JP (4) JP5711352B2 (enExample)
KR (2) KR102006200B1 (enExample)
CN (2) CN103080122A (enExample)
AU (2) AU2011232627B2 (enExample)
BR (1) BR112012023950A2 (enExample)
CA (1) CA2793884C (enExample)
DK (1) DK2550286T3 (enExample)
ES (1) ES2564097T3 (enExample)
HR (1) HRP20160168T1 (enExample)
IL (1) IL222018B (enExample)
MX (1) MX361413B (enExample)
MY (1) MY162411A (enExample)
NZ (1) NZ602544A (enExample)
PL (1) PL2550286T3 (enExample)
RU (1) RU2650883C2 (enExample)
SI (1) SI2550286T1 (enExample)
WO (1) WO2011119604A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1638549A4 (en) 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc NEW ANTIBACTERIAL AGENTS
CA2703475A1 (en) 2007-10-25 2009-04-30 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
US8796232B2 (en) 2008-10-24 2014-08-05 Cempra Pharmaceuticals, Inc. Methods for treating resistant diseases using triazole containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
JP5914335B2 (ja) 2009-09-10 2016-05-11 センプラ ファーマシューティカルズ，インコーポレイテッド マラリア、結核、及びｍａｃ病の治療方法
CN103080122A (zh) * 2010-03-22 2013-05-01 森普拉制药公司 大环内脂的结晶形式及其用途
WO2011146829A1 (en) 2010-05-20 2011-11-24 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates therefor
JP6042334B2 (ja) 2010-09-10 2016-12-14 センプラ ファーマシューティカルズ，インコーポレイテッド 疾患治療のための水素結合形成フルオロケトライド
CN104470527B (zh) 2012-03-27 2019-05-28 森普拉制药公司 用于施用大环内酯抗生素的肠胃外制剂
RU2015138796A (ru) 2013-03-14 2017-04-19 Семпра Фармасьютикалс, Инк. Способы и составы для лечения респираторных заболеваний
WO2014145210A1 (en) 2013-03-15 2014-09-18 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
JP6437523B2 (ja) 2013-04-04 2018-12-12 プレジデント アンド フェローズ オブ ハーバード カレッジ マクロライドならびにそれらの調製および使用の方法
BR112017002335A2 (pt) * 2014-08-05 2018-01-16 Cempra Pharmaceuticals, Inc. formulações de suspensão oral em pó de agentes antibacterianos
CN104151382B (zh) * 2014-08-08 2016-09-14 广东东阳光药业有限公司 一种固态大环内酯的晶型
CN104311611B (zh) * 2014-08-13 2017-01-18 广东东阳光药业有限公司 一种制备固态大环内酯的方法
US10633407B2 (en) 2014-10-08 2020-04-28 President And Fellows Of Harvard College 14-membered ketolides and methods of their preparation and use
EP3273969A4 (en) 2015-03-25 2018-11-21 President and Fellows of Harvard College Macrolides with modified desosamine sugars and uses thereof
WO2017061431A1 (ja) * 2015-10-05 2017-04-13 富山化学工業株式会社 ソリスロマイシンを含む錠剤
EP3190122A1 (en) * 2016-01-08 2017-07-12 LEK Pharmaceuticals d.d. A novel synthetic pathway towards solithromycin and purification thereof
TW201811811A (zh) * 2016-09-02 2018-04-01 森普拉製藥公司 製備氟酮內酯之方法
CN115003309B (zh) 2019-12-02 2024-05-24 阿里量子解决方法公司 一种具有结构式i的化合物的晶型

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
IL99995A (en) 1990-11-21 1997-11-20 Roussel Uclaf Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
US5985844A (en) 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
FR2697524B1 (fr) 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2718450B1 (fr) 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
FR2739620B1 (fr) 1995-10-09 1997-12-19 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
FR2742757B1 (fr) 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2745290B1 (fr) 1996-02-28 1998-04-03 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
SK285534B6 (sk) 1996-09-04 2007-03-01 Abbott Laboratories 6-O-substituované ketolidy s antibakteriálnou aktivitou, farmaceutická kompozícia s ich obsahom, ich použitie a spôsob ich prípravy
HN1998000086A (es) 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
US6407074B1 (en) 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
CN1259135A (zh) 1997-06-11 2000-07-05 辉瑞产品公司 9－肟红霉素衍生物
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
IL135792A0 (en) 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
FR2777282B1 (fr) 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
FR2785612A1 (fr) 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
KR100317907B1 (ko) * 1998-11-24 2001-12-24 김 완 주 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법
FR2786188B1 (fr) 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
ES2273964T3 (es) 1998-12-10 2007-05-16 Pfizer Products Inc. Antibioticos de carbamato y carbazato cetolida.
AP2001002222A0 (en) 1999-01-27 2001-09-30 Pfizer Prod Inc Ketolide antibiotics.
CA2292359C (en) 1999-01-28 2004-09-28 Pfizer Products Inc. Novel azalides and methods of making same
IL145976A0 (en) 1999-04-16 2002-07-25 Ortho Mcneil Pharm Inc Ketolide antibacterials
US6395710B1 (en) 1999-04-16 2002-05-28 Kosan Biosciences, Inc. Macrolide antiinfective agents
US6420535B1 (en) 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
AU6183700A (en) 1999-08-06 2001-03-05 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
KR100336447B1 (ko) 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
CN1193036C (zh) 2000-03-15 2005-03-16 韩美药品工业株式会社 制备甲红霉素－克拉霉素ⅱ型晶体的方法
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
ATE322249T1 (de) 2001-05-18 2006-04-15 Chiron Corp System zur abgabe einer tobramycin-formulierung
JP4509553B2 (ja) 2001-07-03 2010-07-21 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗菌活性を有するｃ１２修飾エリスロマイシンマクロライドおよびケトライド
US20030176327A1 (en) 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
US20040019012A1 (en) 2002-02-22 2004-01-29 Singh Satish K. Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
WO2003101972A1 (en) 2002-05-30 2003-12-11 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
AR043050A1 (es) 2002-09-26 2005-07-13 Rib X Pharmaceuticals Inc Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos
ITMI20022292A1 (it) 2002-10-29 2004-04-30 Zambon Spa 9a-azalidi ad attivita' antiinfiammatoria.
EP1638549A4 (en) 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc NEW ANTIBACTERIAL AGENTS
EP1618120A2 (en) 2003-04-25 2006-01-25 Chiron Corporation Novel ketolide derivatives
WO2005007143A2 (en) 2003-07-14 2005-01-27 The Board Of Trustees Of The University Of Illinois Use of makrolides and ketolides for the treatment of tuberculosis
US7457520B2 (en) 2003-07-24 2008-11-25 Time Warner Cable, Inc. Technique for providing a virtual digital video recorder service through a communications network
US20060116336A1 (en) 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
EP1742957B1 (en) 2004-04-28 2007-09-12 Alembic Limited Process for the preparation of telithromycin
RU2397987C2 (ru) 2004-07-28 2010-08-27 Рэнбакси Лабораториз Лимитед Кетолидные производные в качестве антибактериальных агентов
EP2233493A1 (en) * 2004-12-21 2010-09-29 Pfizer Products Inc. Macrolides
DE602006016231D1 (de) 2005-01-14 2010-09-30 Glaxosmithkline Zagreb 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl-y-aminopropyl-azalide mit antimalaria-aktivität
WO2007039914A2 (en) 2005-10-06 2007-04-12 Alembic Limited Novel polymorphs of telithromycin
US20070167382A1 (en) * 2005-11-15 2007-07-19 Nina Finkelstein Crystalline and amorphous forms of telithromycin
WO2007060627A2 (en) 2005-11-23 2007-05-31 Ranbaxy Laboratories Limited Use of macrolide derivatives for treating acne
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CN101129383B (zh) 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
US7742562B2 (en) * 2007-06-27 2010-06-22 Accuray Incorporated Lower-torso assembly of a treatment couch useable in an X-ray environment
WO2009053259A1 (en) * 2007-10-25 2009-04-30 Sandoz Ag Process for the production of telithromycin
CA2703475A1 (en) 2007-10-25 2009-04-30 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
US8796232B2 (en) * 2008-10-24 2014-08-05 Cempra Pharmaceuticals, Inc. Methods for treating resistant diseases using triazole containing macrolides
US20130045937A1 (en) 2010-03-10 2013-02-21 Cempra Pharmaceuticals, Inc. Parenteral formulations of macrolide antibiotics
CN103080122A (zh) * 2010-03-22 2013-05-01 森普拉制药公司 大环内脂的结晶形式及其用途

Similar Documents

Publication Publication Date Title
JP2012144574A5 (enExample)
MY184306A (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
JP2013525444A5 (enExample)
WO2013040286A3 (en) Pharmaceutical compositions
WO2012021796A3 (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
WO2012018534A3 (en) Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
WO2012142093A3 (en) 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2012009715A3 (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
BR112013030045A2 (pt) composto da fórmula d-m-d ou um sal farmacêuticamente aceitável do mesmo; composto ou sal; composição farmacêutica; e método de tratamento de infecção por hepatite c em um paciente
WO2013066835A3 (en) Compounds and methods
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2013019561A8 (en) Nuclear transport modulators and uses thereof
JP2011037901A5 (enExample)
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
PE20120989A1 (es) Sales de disacarina, acido difumarico, acido d-1-hidroxi-2-naftoico y monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il) metil) fenil) acetato de 4-(dimetilamino) butilo
JP2013532687A5 (enExample)
HK1215579A1 (zh) 被取代的2，3-二氫苯並呋喃基化合物和其用途
UA110983C2 (uk) Похідна 1,2,3,4-тетрагідрохіноліну, придатна для лікування діабету
HK1211290A1 (en) Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
EA033054B1 (ru) Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
WO2013028818A8 (en) Pyrimido- pyridazinone compounds and use thereof
WO2013100567A8 (en) Phenyl carbamate compounds for use in alleviating or treating pain and neuropathic pain